The role of the DNA hypermethylating agent Budesonide in the decatenating activity of DNA topoisomerase II

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 694, Issue 1-2, 2010, Pages 45-52

  Orta, Manuel Luis ^a   Domínguez, Inmaculada ^a   Pastor, Nuria ^a   Cortés, Felipe ^a   Mateos, Santiago ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Chromosome segregation; Endoreduplication; Hypermethylation of DNA; Topoisomerase II

Indexed keywords

AMSACRINE; AZACITIDINE; BUDESONIDE; DNA TOPOISOMERASE (ATP HYDROLYSING);

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CYCLE; CHROMOSOME SEGREGATION; CONTROLLED STUDY; DNA CLEAVAGE; DNA CONFORMATION; DNA DAMAGE; DNA METHYLATION; DNA SEQUENCE; ENDOREDUPLICATION; ENZYME ACTIVITY; EPIGENETICS; HAMSTER; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AZACITIDINE; BUDESONIDE; CELL CYCLE; CELL NUCLEUS; CHROMOSOMES; CRICETINAE; DNA METHYLATION; DNA REPLICATION; DNA TOPOISOMERASES, TYPE II; FLOW CYTOMETRY; GLUCOCORTICOIDS; HUMANS; MICROSCOPY, FLUORESCENCE; MITOSIS;

CRICETULUS GRISEUS;

EID: 78649451968     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2010.09.004     Document Type: Article

References (64)

1. Wang DNA topoisomerases. Annu. Rev. Biochem. 1996, 65:635-692.
2. Champoux J.J. DNA topisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 2001, 70:369-413.
3. Uemura T., Ohkura H., Adachi Y., Morino K., Shiozaki K., Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. Pombe. Cell 1987, 50:817-925.
4. Downes C.S., Mullinger A.M., Johnson R.T. Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:2616-2620.
5. Shamu C.E., Murray A.W. Sister chromatid separation in frog extracts requires topoisomerase II activity during anaphase. J. Cell Biol. 1992, 117:921-934.
6. Buchenau P., Saumweber H., Arndt-Jovin D.L. Consequences of topoisomerase II inhibition in early embryogenesis of Drosophila revealed by in vivo confocal laser scanning microscopy. J. Cell Sci. 1993, 104:1175-1185.
7. Giménez-Abián J.F., Clarke D.J., Mullinger A.M., Downes C.S., Johnson R.T. A postprophase topoisomerase II dependent chromatid core separation step in the formation of metaphase chromosomes. J. Cell Biol. 1995, 131:7-17.
8. Sumner A.T. Inhibitors of topoisomerase II delay progress through mitosis and induce doubling of the DNA content in CHO cells. Exp. Cell. Res. 1995, 217:440-447.
9. Sumner A.T. Induction of diplochromosomes in mammalian cells by inhibitors of topoisomerase II. Chromosoma 1998, 107:486-490.
10. DiNardo S., Voelkel K., Sternglanz R. DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:2616-2620.
11. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 1989, 58:351-375.
12. Andoh T., Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta 1998, 1400:155-171.
13. Pastor N., Flores M.J., Domínguez I., Mateos S., Cortés F. High yield of endoreduplication induced by ICRF-193, a topoisomerase II catalytic inhibitor. Mutat. Res. 2002, 516:113-120.
14. Cantero G., Pastor N., Mateos S., Campanella C., Cortés F. Cisplatin-induced endoreduplication in CHO cells: DNA damage and inhibition of topoisomerase II. Mutat. Res. 2006, 599:160-166.
15. Ishida R., Sato M., Narita T., Utsumi K.R., Nishimoto T., Morita T., Nagata H., Andoh T. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J. Cell Biol. 1994, 126:1341-1351.
16. Sander M., Hsieh T., Udvardy A., Schedl P. Sequence dependence of Drosophila topoisomerase II in plasmid relaxation and DNA binding. J. Mol. Biol. 1987, 194:219-229.
17. Spitzner J.R., Muller M.T. A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res. 1988, 16:5533-5556.
18. Lee M.P., Sander M., Hsieh T. Nuclease protection by Drosophila DNA topoisomerase II. Enzyme/DNA contacts at the strong topoisomerase II cleavage sites. J. Biol. Chem. 1989, 264:21779-21787.
19. Pommier Y., Capranico G., Orr A., Kohn K.W. Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs. J. Mol. Biol. 1991, 222:909-924.
20. Cortés F., Pastor N., Mateos S., Domínguez I. The nature of DNA plays a role in chromosome segregation: endoreduplication in halogen-substituted chromosomes. DNA Repair (Amst) 2003, 2:719-726.
21. Cantero G., Mateos S., Pastor N., Cortés F. Halogen substitution of DNA protects from poisoning of topoisomerase II that results in DNA double-strand breaks. DNA Repair 2006, 5:667-674.
22. Mateos S., Domínguez I., Pastor N., Cantero G., Cortés F. The DNA demethylating 5-azaC induces endoreduplication in cultured Chinese hamster cells. Mutat. Res. 2005, 578:33-42.
23. Heartlein M.W., Tsuji H., Latt S.A. 5-Bromodeoxyuridine-dependent increase in sister chromatid exchange formation in Bloom's syndrome is associated with reduction in topoisomerase II activity. Exp. Cell Res. 1987, 169:245-254.
24. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
25. Pereira M.A., Li Y., Gunning W.T., Kramer P.M., Alyaqoub F.S., Lubet R.A., Steele V.E., Szabo E., Kramer P.M. Prevention of mouse lung tumour by Budesonide and its modulation of biomarkers. Carcinogenesis 2002, 23:1185-1192.
26. Tao L., Li Y., Wang W., Kramer P.M., Gunning W.T., Lubet R.A., Steele V.E., Pereira M.A. Effect of Budesonide on the methylation and mRNA expression of the insulin-like growth factor 2 and c-myc genes in mouse lung tumors. Mol. Carcinogen. 2002, 35:93-102.
27. Mateos S., Domínguez I., Cantero G., Pastor N., Campanella C., Cortés F. The high rate of endoreduplication in the repair deficient CHO mutant EM9 parallels a reduced level of methylated deoxycytidine in DNA. Mutat. Res. 2008, 644:24-30.
28. Jaenisch R., Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 2003, 33(Suppl.):245-254.
29. Jones P.A., Gonzalgo M.L. Altered DNA methylation and genome instability: a new pathway to cancer?. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:2103-2105.
30. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21:5400-5413.
31. Gonzalgo M.L, Jones P.A. Mutagenic and epigenetic effects of DNA methylation. Mutat. Res. 1997, 386:107-118.
32. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
33. Pogribny I., Yi P., James S.J. A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem. Biophys. Res. Commun. 1999, 262:624-628.
34. Wachsman J.T. DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis. Mutat. Res. 1997, 375:1-8.
35. Rauch T.A., Zhnog X., Wu X., Wang M., Kernstine K.H., Wang Z., Riggs A.D., Pfeifer G.P. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. PNAS 2008, 105:252-257.
36. Kuzmin, Geil L. DNA methylation and chromatin modifications in cancer and development. Int. Arch. Biosci. 2001, 1047-1056.
37. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chem. Pharmacol. 1993, 32:103-108.
38. Cortes F., Mateos S., Pastor N., Dominguez I. Toward a comprehensive model for induced endoreduplication. Life Sci. 2004, 26:121-135.
39. Kirchner S., Schiffmann D., Stopper H. The influence of DNA methylation on topoisomerase II activity and its possible link with genome instability in different cell lines of the Syrian hamster. Toxicol. In Vitro 1995, 9:519-525.
40. Jones P.A. DNA methylation and cancer. Oncogene 2002, 21:5358-5360.
41. Jones P.A., Takai .D. The role of DNA methylation in mammalian epigenetics. Science 2001, 293:1068-1070.
42. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 2002, 3:662-673.
43. Siegfried Z., Eden S., Mendelsohn M., Feng X., Tsuberi B.Z., Cedar H. DNA methylation represses transcription in vivo. Nat. Genet. 1999, 22:203-206.
44. Costello J.F., Plass C. Methylation matters. J. Med. Genet. 2001, 38:285-303.
45. Ng H.H., Bird A. DNA methylation and chromatin modification. Curr. Opin. Genet. Dev. 1999, 9:158-163.
46. Duncan B.K., Miller J.H. Mutagenic deamination of cytosine residues in DNA. Nature 1980, 287:560-561.
47. Rodenhiser D., Mann M. Epigenetics and human disease translating basic biology into clinical applications. CMAJ 2006, 174:341-348.
48. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
49. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61:3225-3229.
50. Hoffmann M.J., Schulz W.A. Causes and consequences of DNA hypomethylation in human cancer. Biochem. Cell Biol. 2005, 83:296-321.
51. Brena R.M., Costello J.F. Genome-epigenome interactions in cancer. Hum. Mol. Genet. 2007, 16(Spec No. 1):R96-R105.
52. Li L.C. Epigenetics of prostate cancer. Front Biosci. 2007, 12:3377-3397.
53. Agrawal A., Murphy R.F., Agrawal D.K. DNA methylation in breast and colorectal cancers. Mod. Pathol. 2007, 20:711-721.
54. Wilson A.S., Power B.E., Molloy P.L. DNA hypomethylation and human diseases. Biochim. Biophys. Acta 2007, 1775:138-162.
55. Miremadi A., Oestergaard M.Z., Pharoah P.D., Caldas C. Cancer genetics of epigenetic genes. Hum. Mol. Genet. 2007, 16(Spec No. 1):R28-R49.
56. Pommier Y., Orr A., Kohn K.W., Riou J.-F. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human C-Myc protooncogene. Cancer Res. 1992, 52:3125-3130.
57. Veeck J., Chorovicer M., Naami A., Breuer E., Zafrakas M., Bektas N., Dürst M., Kristiansen G., Wild P.J., Hartmann A., Knuechel R., Dahl E. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Oncogene 2008, 27:865-876.
58. Umetani N., Mori T., Koyanagi K., Shinozaki M., Kim J., Giuliano A.E., Hoon D.S.B. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 2005, 24:4721-4727.
59. Murata H., Khattar N.H., Gu L., Li G.M. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett. 2005, 223:143-150.
60. Takahashi Y., Miyoshi Y., Takahata C., Irahara N., Taguchi T., Tamaki Y., Noguchi S. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin. Cancer Res. 2005, 11:1380-1385.
61. Osanai T., Takagi Y., Toriya Y., Nakagawa T., Azuga T., Lida S., Uetake H., Sigihara K. Inverse correlation between the expression of O6-methylguanine-DNA methyltransferase (MGMT) and p53 in breast cancer. Jpn. J. Clin. Oncol. 2005, 35:121-125.
62. Li X., Cowell J.K., Sossey-Alaoui K. CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer. Oncogene 2004, 23:1474-1480.
63. Yang D., Thangaraju M., Greeneltch K., Browning D.D., Schoenlein P.V., Schoenlein T., Tamura T., Ozato K., Ganapathy V., Abrams S.I., Liu K. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res. 2007, 67:3301-3309.
64. Hu X.C., Wong I.H., Chow L.W. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. Oncol. Rep. 2003, 10:1811-1815.